false
--12-31
0001419554
0001419554
2023-12-14
2023-12-14
0001419554
BBLG:CommonStockParValue0.001PerShareMember
2023-12-14
2023-12-14
0001419554
BBLG:WarrantsToPurchaseCommonStock0.001ParValuePerShareMember
2023-12-14
2023-12-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): December
14, 2023
BONE
BIOLOGICS CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40899 |
|
42-1743430 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2
Burlington Woods Drive,
Ste.
100
Burlington,
MA |
|
01803 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(Registrant’s
telephone number, including area code): (781)
552-4452
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
BBLG |
|
Nasdaq
Capital Market |
|
|
|
|
|
Warrants
to Purchase Common Stock, $0.001 par value per share |
|
BBLGW |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.03 Material Modification to Rights of Security Holders.
On
December 14, 2023, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated
Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Certificate
of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”)
at a ratio of 1-for-8 shares, effective as of 12:01 a.m. Eastern Time on December 20, 2023 (the “Reverse Stock Split”).
The
Company expects that the Common Stock will begin trading on a post-split basis under its existing trading symbol, “BBLG,”
when the market opens on December 20, 2023. The Company’s warrants will continue to be traded under the symbol “BBLGW.”
The new CUSIP identifier for the Common Stock following the Reverse Stock Split will be 098070501 and the CUSIP for the warrants will
remain unchanged.
As
a result of the Reverse Stock Split, every 8 shares of Common Stock will be automatically combined into one share of Common Stock. The
total number of authorized shares of Common Stock will remain the same following the Reverse Stock Split. Any fractional shares resulting
from the Reverse Stock Split will be rounded up to the nearest whole share. Proportionate adjustments for the Reverse Stock Split will
be made to the per share exercise price and the number of shares issuable upon the exercise of warrants, the number of shares reserved
for issuance under the Company’s equity plans, and all then-outstanding awards under the Company’s equity plans, as applicable.
The Reverse Stock Split will not change the par value of the Common Stock or modify any voting rights or other terms of the Common Stock.
The
foregoing summary of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the
full text of the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
To
the extent required by Item 5.03 of Form 8-K, the information contained in Item 3.03 of this Current Report on Form 8-K is incorporated
herein by reference.
Item
8.01 Other Events.
On
December 18, 2023, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as
Exhibit 99.1 to this report.
Forward-Looking
Statements
Certain
statements contained in this report, including, without limitation, statements regarding the timing, implementation, and success of the
Reverse Stock Split, as well as statements containing the words “expect,” “will,” and words of similar import,
constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially
from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and
other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk
Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s
Annual Repot on Form 10-K for the year ended December 31, 2022 and the Company’s other filings with the Securities and Exchange
Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect
any event or circumstance that may arise after the date hereof.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
BONE
BIOLOGICS CORPORATION |
Date:
December 18, 2023 |
|
|
|
By: |
/s/ Jeffrey Frelick |
|
|
Jeffrey
Frelick |
|
|
Chief
Executive Officer |
Exhibit
3.1
CERTIFICATE
OF AMENDMENT
OF
THE
AMENDED
AND RESTATED
CERTIFICATE
OF INCORPORATION
OF
BONE
BIOLOGICS CORPORATION
Bone
Biologics Corporation, a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation
Law (the “DGCL”), does hereby certify as follows:
FIRST:
The name of the corporation is Bone Biologics Corporation (the “Corporation”).
SECOND:
The Amended and Restated Certificate of Incorporation was filed with the Secretary of the State of Delaware on July 28, 2014, as
was amended by those Certificate of Amendments filed with the Secretary of State of the State of Delaware on September 22, 2014, July
16, 2018, October 8, 2021 and June 5, 2023 (the “Certificate of Incorporation”).
THIRD:
Article 5 of the Certificate of Incorporation is hereby amended in its entirety to provide as follows:
“The
total number of shares of capital stock which the Corporation shall have authority to issue is: One Hundred Twenty Million (120,000,000).
These shares shall be divided into two classes with 100,000,000 shares designated as common stock at $0.001 par value (the “Common
Stock”) and 20,000,000 shares designated as preferred stock at $0.001 par value (the “Preferred Stock”).
Effective
at 12:01 AM Eastern Time on December 20, 2023 (the “Effective Time”), pursuant to the DGCL, this Certificate of Amendment
to the Amended and Restated Certificate of Incorporation of the Corporation, as amended, each eight (8) shares of Common Stock outstanding
immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be
converted into one (1) share of Common Stock (the “Reverse Stock Split”). No fractional shares shall be issued in connection
with the Reverse Stock Split. Stockholders of record who otherwise would be entitled to receive fractional shares of Common Stock because
they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will automatically be entitled to receive an additional
fraction of a share of Common Stock to round up to the next whole share. Each certificate that immediately prior to the Effective Time
represented shares of Common Stock (“Old Certificates”), shall thereafter represent that number of shares of Common Stock
into which the shares of Common Stock represented by the Old Certificate shall have been converted, subject to the elimination of fractional
share interests as described above.
The
Preferred Stock of the Corporation shall be issued by the Board of Directors of the Corporation in one or more classes or one or more
series within any class and such classes or series shall have such voting powers, full or limited, or no voting powers, and such designations,
preferences, limitations or restrictions as the Board of Directors of the Corporation may determine, from time to time.
Holders
of shares of Common Stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes,
including the election of directors. The Common Stock does not have cumulative voting rights.
No
holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any
new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now
hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.”
FOURTH:
This Certificate of Amendment shall become effective on December 20, 2023 at 12:01 AM Eastern Time.
FIFTH:
This Certificate of Amendment was duly adopted by the Board of Directors of the Corporation and approved by the Corporation’s
stockholders in accordance with Section 242 of the DGCL.
[Signature
page follows.]
IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer on this 14th
day of December, 2023.
|
Bone
Biologics Corporation |
|
|
|
|
By: |
|
|
Name:
|
Jeffrey
Frelick |
|
Title: |
Chief
Executive Officer |
Exhibit
99.1
Bone
Biologics Announces 1-for-8 Reverse Stock Split
BURLINGTON,
Mass., December 18, 2023 — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG,
BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares
of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, December 20, 2023,
and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “BBLG,”
at the market open on December 20, 2023.
At
the Company’s special meeting of stockholders held on December 12, 2023, stockholders approved an amendment to the Company’s
Amended and Restated Certificate of Incorporation to implement a reverse stock split in a range of 1-for-5 to 1-for-20, and granted the
board of directors the authority to implement and determine the exact split ratio within such range, which was subsequently set by the
board at 1-for-8. Following the reverse stock split, the new CUSIP number of the common stock will be 098070501, with the par value per
share of common stock remaining at $0.001. A proportionate adjustment will be made to the per-share exercise prices and number of shares
issuable under all outstanding warrants and equity awards.
When
the reverse stock split becomes effective, every eight shares of the Company’s issued and outstanding common stock will be combined
into one share of common stock. Each stockholder’s percentage ownership interest in Bone Biologics will remain unchanged after
the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share of
common stock. The number of authorized shares of common stock of the Company will remain the same following the reverse stock split.
About
Bone Biologics
Bone
Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds
on the preclinical research of the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft substitute
product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For
more information, please visit www.bonebiologics.com.
Forward-Looking
Statements
Certain
statements contained in this press release, including, without limitation, statements regarding the timing, implementation, and success
of the reverse stock split, as well as statements containing the words “plan,” “will,” and words of similar import,
constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially
from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and
other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk
Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2022 and the Company’s other filings with the Securities and Exchange
Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect
any event or circumstance that may arise after the date hereof.
Contacts:
LHA
Investor Relations
Kim
Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
v3.23.4
Cover
|
Dec. 14, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 14, 2023
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-40899
|
Entity Registrant Name |
BONE
BIOLOGICS CORPORATION
|
Entity Central Index Key |
0001419554
|
Entity Tax Identification Number |
42-1743430
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2
Burlington Woods Drive
|
Entity Address, Address Line Two |
Ste.
100
|
Entity Address, City or Town |
Burlington
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
01803
|
City Area Code |
781
|
Local Phone Number |
552-4452
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock, par value $0.001 per share |
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
Trading Symbol |
BBLG
|
Security Exchange Name |
NASDAQ
|
Warrants to Purchase Common Stock, $0.001 par value per share |
|
Title of 12(b) Security |
Warrants
to Purchase Common Stock, $0.001 par value per share
|
Trading Symbol |
BBLGW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BBLG_CommonStockParValue0.001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BBLG_WarrantsToPurchaseCommonStock0.001ParValuePerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Oct 2023 to Oct 2024